



#28  
Dover  
3-21-03

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: March 3, 2003

By:

*Kay L. Gaviglio*  
Kay L. Gaviglio

PATENT  
Docket No. GC566-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )

Jones et al. )

Serial No.: 09/436,513 )

Filed: November 9, 1999 )

For: Chemically Modified Mutant Serine )  
Hydrolases Show Improved Catalytic )  
Activity And Chiral Selectivity )

Group Art Unit: 1652

Examiner: Patterson, Charles L. Jr.

RECEIVED  
MAR 17 2003  
TC 1700  
TECH CENTER 1600/2900

Information Disclosure Statement

Commissioner for Patents  
Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

Also, those patent(s) or publication(s) which are marked with an asterisk (\*) on the attached Form PTO-1449 (**Books not sent**) are not supplied. Complete bibliographic information is unknown or unavailable. The cited publications are books or reference manuals and are commonly available. Reproduction of such publications would result in a voluminous submission.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


This is a resubmission of an Invention Disclosure Statement previously submitted (*See Response Dated December 7, 2003*) and the copies of the references can be found in that filing.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is

Serial No. 09/436,513  
Page 3

in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,



H. Thomas Anderton, Jr.  
Registration No. 40,895

Date: March 3, 2003

Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650 846-7544  
Fax: 650 845-6504